Hikma Pharmaceuticals PLC

HIK

Equity

ISIN GB00B0LCW083 / Valor 2324471

LSE London Stock Exchange, SETS (2024-09-18)

GBP 19.14-0.05%

Hikma Pharmaceuticals PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Hikma Pharmaceuticals PLC is a leading pharmaceutical company in the MENA region, supplying branded generics and in-licensed patented products to retail and hospital customers. With a global presence, the company operates 29 manufacturing plants, eight R&D centers, and employs approximately 9,100 people worldwide. Hikma manufactures and supplies over 760 products essential for healthcare professionals in North America, MENA, and Europe, catering to the needs of hospitals, physicians, and pharmacists.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Hikma Pharmaceuticals PLC reported a 10% increase in Group revenue for the first half of 2024, reaching $1,569 million compared to $1,427 million in the same period of 2023. This growth was driven by strong performances across all three of its business segments: Injectables, Branded, and Generics.

Operating Profit

The Group's operating profit saw a significant rise of 43% in H1 2024, amounting to $351 million, up from $245 million in H1 2023. This increase was attributed to the robust performance of the Branded business and the strategic focus on higher-margin products.

Core EBITDA

Hikma Pharmaceuticals PLC maintained a strong core EBITDA margin of 28.9% in H1 2024, although slightly down from 31.6% in H1 2023. The core EBITDA for the period was $453 million, reflecting the company's efficient cost management and operational effectiveness.

Interim Dividend

The company declared an interim dividend of 32 cents per share for H1 2024, representing a 28% increase from the 25 cents per share declared in H1 2023. This increase underscores Hikma's commitment to returning value to its shareholders.

Outlook for 2024

Hikma Pharmaceuticals PLC has upgraded its full-year 2024 guidance, now expecting Group revenue growth of 6% to 8%, up from the previous forecast of 4% to 6%. Additionally, the Group core operating profit is projected to be between $700 million and $730 million, reflecting the company's strong performance and positive market outlook.

Summarized from source with an LLMView Source

Key figures

-8.86%1Y

-21.0%3Y

-4.64%5Y

Performance

23.4%1Y

27.6%3Y

28.6%5Y

Volatility